Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 15/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198318 | 0.93 | PTPN1 (0.43) | PTPN1PTPN2PTPRCCYP2C9GAA | |
| SCHEMBL3192752 | 0.86 | PTPN1 (0.66) | PTPN1PTPN2PTPRCCYP2C9 | |
| SCHEMBL3190713 | 0.83 | GABRA1 (0.41) | PTPN1PTPN2 | |
| SCHEMBL3192974 | 0.82 | PTPN1 (0.41) | PTPN1PTPN2 | |
| SCHEMBL3203156 | 0.81 | PTPN1 (0.53) | PTPN1PTPN2PTPRCCYP2C9GAA | |
| SCHEMBL3915924 | 0.81 | PTPN1 (0.74) | PTPN1PTPN2PTPRCCYP2C9 | |
| SCHEMBL3202952 | 0.80 | PTPN1 (0.55) | PTPN1PTPN2PTPRCCYP2C9 | |
| SCHEMBL3200686 | 0.80 | PTPN1 (0.43) | PTPN1PTPN2MAPTNPSR1ALDH1A1 | |
| SCHEMBL3191253 | 0.79 | SIGMAR1 (0.41) | PTPN1ALDH1A1HSD17B10 | |
| SCHEMBL3906665 | 0.79 | PTPN1 (0.77) | PTPN1PTPN2PTPRCCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674822-B2 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | PTPA, PTPRCAP, PTPRC | PTPN1 22/4885PTPN2 14/4885PTPRC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.